New blood test registry aims to improve neuroendocrine tumor care
NCT ID NCT02270567
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This registry is collecting blood samples and health data from 400 people with neuroendocrine tumors. The goal is to see if a new blood test called NETest can help detect tumor activity and predict disease progression. Participants include patients before and after surgery, those on watchful waiting, and those receiving various treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NETest blood test
- What this could lead to
- If successful, this registry could help validate a simple blood test to detect neuroendocrine tumor activity and guide treatment decisions.
- What could go wrong
- This is an observational registry, not a treatment trial. It will not directly test whether the blood test improves patient outcomes, and results may take years to analyze.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHOPULMONARY NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Wren Laboratories
Branford, Connecticut, 06405, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a black seed extract boost immunotherapy against a rare cancer?
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a radioactive drug shrink Slow-Growing tumours?
- New drug cocktail aims to fight rare cancer
- Double-Action antibody takes on Hard-to-Treat neuroendocrine cancers
- Two-Drug combo aims to stall rare gut tumors